Back to top
more

Syndax Pharmaceuticals (SNDX)

(Delayed Data from NSDQ)

$19.00 USD

19.00
3,994,862

-0.04 (-0.21%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $18.95 -0.05 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised

by Zacks Equity Research

Puma Biotechnology beats third-quarter estimates for earnings and revenues and lifts its 2025 outlook on stronger Nerlynx sales.

Zacks Equity Research

ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth

by Zacks Equity Research

Acadia's third-quarter earnings and revenues top forecasts as Nuplazid and Daybue sales power double-digit annual growth.

Zacks Equity Research

TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up

by Zacks Equity Research

Teva stock jumps after third-quarter earnings and revenues top estimates, driven by robust Austedo sales as well as U.S. generics growth.

Zacks Equity Research

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Syndax (SNDX) delivered earnings and revenue surprises of +5.41% and -5.79%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Wall Street Analysts Believe Syndax (SNDX) Could Rally 112.8%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Syndax (SNDX) points to an 112.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Agilent Q3 Earnings Beat Estimates, Revenues Up Y/Y, Shares Rise

by Zacks Equity Research

A posts fiscal Q3 earnings and revenue beats, with double-digit sales growth and upbeat guidance lifting shares.

Zacks Equity Research

Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Syndax (SNDX) points to a 158.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Syndax (SNDX) delivered earnings and revenue surprises of +17.00% and +30.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

All You Need to Know About Syndax (SNDX) Rating Upgrade to Buy

by Zacks Equity Research

Syndax (SNDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.